Alecensa is the first and only anaplastic lymphoma kinase inhibitor approved for use in non-small cell lung cancer.

Published Date: 24 Apr 2024

The USA. s. The FDA has authorized Alecensa (alectinib) from Genentech as an adjuvant treatment for patients with non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) after tumor resection.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot